Cingulate reports $22.4M FY2025 net loss, CTx-1301 patent allowed, PDUFA May 2026

Cingulate Inc.

Net loss of $22.4M for 2025 vs $16.6M in 2024; Q4 net loss $6.3M.
Cash $11.0M at Dec 31, 2025; expects runway into late Q4 2026.
USPTO Notice of Allowance for CTx-1301 patent; protection through May 2042.
NDA for CTx-1301 accepted under 505(b)(2); PDUFA target date May 31, 2026.
Closed $12M at-the-market PIPE in Feb 2026 led by Falcon Creek Capital; 180-day lock-up.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.